Pharmaceuticals
Lantern Pharma Expands predictBBB Platform into Large Quantitative Model for Drug Discovery
Lantern Pharma announced the expansion of its predictBBB platform into a Large Quantitative Model (LQM), enabling real-time molecular intelligence for drug discovery, which could accelerate development and reduce costs.
LakeShore Biopharma Amends Merger Agreement, Slashes Share Consideration to $0.066 in Going-Private Deal
LakeShore Biopharma has amended its merger agreement to take the company private at a reduced equity value of $2.7 million, offering $0.066 per share after a revised proposal from the buyer group.
Earth Science Tech Positions Itself for Telehealth's Next Phase with Integrated Platform
Earth Science Tech Inc. is aligning with the evolution of telehealth from simple video visits to a comprehensive care model through its integrated platform that combines telemedicine, compounding pharmaceuticals, and patient services.
Telomir Pharmaceuticals Closes TELI Acquisition, Secures Global Rights to Lead Drug Candidate
Telomir Pharmaceuticals completed its acquisition of TELI Pharmaceuticals, obtaining sole global rights to Telomir-1, a drug aimed at treating advanced breast cancer and targeting aging-related diseases, with a $1 million upfront payment and up to $4 million in milestones.
Scinai Immunotherapeutics Raises $2.61M to Expand CDMO Platform and Advance Pipeline
Scinai Immunotherapeutics announced a $2.61 million private placement and warrant inducement, with proceeds supporting its CDMO expansion and immunotherapy pipeline.
Oncotelic Therapeutics Featured in NetworkNewsAudio Editorial Highlighting How Late-Stage Drug Pipelines Drive Valuation in Biotech
Oncotelic Therapeutics, Inc. (OTCQB: OTLC) is featured in a NetworkNewsAudio editorial that explores how advancing drug pipelines, particularly those near commercialization, create significant value in biopharma, directly relevant to Oncotelic's oncology-focused pipeline.
Oncotelic Therapeutics Highlights Partnership Strategy to Advance Pipeline and Boost Shareholder Value
Oncotelic Therapeutics updates its partnership-driven strategy, citing a $249 million valuation boost from its GMP Biotechnology joint venture and plans for further collaborations to advance its oncology pipeline efficiently.
Tonix Pharmaceuticals Presents Preclinical Immuno-Oncology Data at AACR 2026, Highlighting Potential in Gastric Cancer and Immunotherapy
Tonix Pharmaceuticals announced new preclinical data for TNX-1700 and TNX-4700 at AACR 2026, showing potential in gastric cancer and as a BTLA-targeting immunotherapy, which could expand its oncology pipeline.
Helus Pharma Appoints Robert Langer and Stephen Brannan to Scientific Advisory Board, Bolstering Neuroscience Pipeline
Helus Pharma adds renowned experts Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, strengthening its drug development capabilities for mental health treatments including major depressive disorder and generalized anxiety disorder.
Newron Pharmaceuticals Shareholders Approve New Board Members at AGM 2026
Newron Pharmaceuticals' AGM 2026 approved the election of two independent directors, while extraordinary motions were postponed due to lack of quorum, highlighting shareholder dynamics.
Cingulate Advances ADHD Treatment Toward 2026 FDA Decision with Key Milestones
Cingulate Inc. progresses toward potential 2026 commercial launch of its ADHD treatment CTx-1301 following FDA acceptance of its New Drug Application and positive pediatric trial results, addressing a large market with unmet needs.
Carmed Pharmaceuticals Expands U.S. Market Presence with OneLavi Launch
Carmed Pharmaceuticals is expanding its U.S. distribution by launching products on the curated online marketplace OneLavi, representing a strategic move to increase accessibility and build credibility for its research-driven botanical formulations in the American wellness market.
NRx Pharmaceuticals Receives Positive FDA Review for Ketamine ANDA, Targets 2026 Approval
NRx Pharmaceuticals has received a positive FDA review letter for its ketamine ANDA and reported a supportive meeting with FDA leadership, advancing its preservative-free ketamine product toward potential approval in summer 2026 for treating severe mental illness.
Tonix Pharmaceuticals Publishes Pharmacokinetic Study Supporting TONMYA's Mechanism for Fibromyalgia Treatment
Tonix Pharmaceuticals' peer-reviewed study demonstrates TONMYA's superior pharmacokinetic profile compared to oral cyclobenzaprine, supporting its use as the first new fibromyalgia treatment in over 15 years.
Earth Science Tech Inc. Expands Healthcare Portfolio Through Strategic Holdings
Earth Science Tech Inc. is building a diversified healthcare platform through strategic acquisitions and active management of compounding pharmacies, telehealth services, and community-focused healthcare providers, aiming to create sustainable growth and shareholder value.
Nutriband CEO Discusses AVERSA Technology's Role in Addressing Opioid Crisis on Podcast
Nutriband Inc. CEO Gareth Sheridan highlighted the company's AVERSA abuse-deterrent transdermal technology on a podcast, emphasizing its potential to reduce misuse of high-risk drugs like fentanyl while maintaining patient access.
Oncotelic Therapeutics Exemplifies Biotech Sector's Shift Toward Pipeline-Driven Valuation
Oncotelic Therapeutics illustrates how biotechnology companies are increasingly being valued based on clinical progress and pipeline assets rather than traditional metrics, representing a fundamental shift in sector valuation practices.
Biotech Valuations Shift as Scientific Progress Gains Financial Recognition
The biotechnology industry is undergoing a transformation where scientific advancement is increasingly quantified as financial assets through fair-value accounting, with companies like Oncotelic Therapeutics demonstrating how clinical progress translates to tangible economic value.
Helus Pharma Appoints Neuroscience Veteran Dr. Ken Kramer as Senior Vice President of Medical Affairs
Helus Pharma's appointment of Dr. Ken Kramer, a 20-year neuroscience medical affairs leader, strengthens the company's clinical development capabilities for its novel serotonergic agonists targeting depression and anxiety disorders.
Soligenix Gains EU Orphan Drug Designation for SGX945 in Behçet's Disease, Bolstering Rare Disease Pipeline
The European Commission granted orphan drug designation to Soligenix's SGX945 for Behçet's disease, validating the therapy's potential and supporting the company's rare disease strategy.
Biotech Valuation Shift: Drug Pipeline Progress Now Measured as Financial Assets Under GAAP
The biotech sector is experiencing a transformation where advancing drug pipelines are increasingly valued as financial assets under fair-value accounting, with companies like Oncotelic Therapeutics exemplifying how clinical progress directly impacts balance sheet valuation.
Helus Pharma CEO Steps Down, Co-founder Eric So Appointed Interim Chief
Helus Pharma announced the immediate resignation of CEO Michael Cola and appointment of co-founder Eric So as interim CEO, aiming to ensure continuity during a pivotal phase with upcoming Phase 3 trial results.
Soligenix CEO Advocates for Patient-Centric Reformulation Strategy in Rare Disease Drug Development
Soligenix CEO Christopher Schaber argues that reformulating therapies to better fit patients' daily lives can improve access, adherence, and long-term viability, highlighting a strategic shift in biopharmaceutical development.
Soligenix Gains European Orphan Drug Designation for Behçet's Disease Therapy SGX945
The European Commission granted orphan drug designation to Soligenix's SGX945 for treating Behçet's disease, validating the therapy's potential and providing regulatory and commercial incentives for development in a rare disease area with significant unmet need.
Formycon to Announce 2025 Financial Results and Participate in Key Investor Conferences
Formycon AG will release its 2025 financial results and provide a 2026 outlook during an April conference call, while planning participation in multiple international investor conferences to showcase its biosimilar pipeline amid growing market opportunities.
NanoViricides Highlights NV-387 as Potential Measles Treatment Amid Global Outbreak Concerns
NanoViricides announced its antiviral drug candidate NV-387 may address the growing global measles outbreak, potentially complementing vaccination efforts by reducing transmission and treating infected patients.
Oncotelic Therapeutics Featured in Editorial on Biotech Valuation Trends
Oncotelic Therapeutics' diversified pipeline and strategic holdings, including a 45% stake in GMP Bio valued at over $1 billion, exemplify how scientific progress and commercialization proximity are increasingly recognized as measurable financial assets under U.S. GAAP, reflecting a broader shift in biotech valuation.
Soligenix CEO Emphasizes Capital Discipline as Key to Biotech Success in Constrained Funding Environment
Soligenix CEO Dr. Christopher J. Schaber highlights capital discipline as essential for biotech companies to navigate today's challenging funding landscape, where strategic resource allocation and milestone-focused development are critical for attracting investment and advancing programs toward commercialization.
Soligenix CEO Advocates for Patient-Centric Drug Reformulation to Improve Treatment Access and Adherence
Soligenix CEO Christopher Schaber argues that reformulating therapies to better align with patients' daily lives can enhance treatment access, adherence, and clinical trial success, reflecting a broader industry shift toward patient-centered drug development.
Cybin to Present Neuropsychiatry Pipeline at Jefferies Global Healthcare Conference
Cybin Inc. will present its late-stage neuropsychiatry pipeline including breakthrough-designated depression treatment at the Jefferies Global Healthcare Conference, highlighting the company's progress in developing novel mental health therapies.